Rebecca Garris

Statistics

Publications

Citations

4.6K

H-Index

Active since

2007

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, Irvine

University of California, Irvine Medical Center

Rebecca Garris is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, acute lymphoblastic leukemia treatment, and acute lymphoblastic leukemia therapy.

Publications per year

2007–2025

Publications

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

Farhad Ravandi, Susan O’Brien, Deborah Thomas et al. · Blood · 2010 · 343 citations · Full text

Medicine, Hematology, Oncology +11

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · Cancer · 2013 · 302 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Elias Jabbour, Hagop M. Kantarjian, Farhad Ravandi et al. · The Lancet Oncology · 2015 · 280 citations

Medicine, Hematology, Oncology +13

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

Elias Jabbour, Nicholas J. Short, Farhad Ravandi et al. · The Lancet Haematology · 2018 · 270 citations · Full text

Medicine, Hematology, Oncology +12

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Nicholas J. Short, Elias Jabbour, Koji Sasaki et al. · Blood · 2016 · 253 citations · Full text

Medicine, Hematology, Oncology +12

1–5 of 64